Aerovate Therapeutics Inc
AVTE M | $25.3 0.24% 0.43% 110K
|
Professional, Scientific, and T...
(0.0% 1d) (-4.1% 1m) (39.4% 1y) (0.0% 2d) (0.0% 3d) (-6.3% 7d) (-19.78% volume)
Earnings Calendar: 2024-03-26
Market Cap: $ 704,858,000
https://www.aerovatetx.com
Sec Filling | Patents | 2021 employees
Aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. Aerovate's initial focus is on advancing AV-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or PAH.
treatment
add to watch list Paper trade email alert is off
Press-releases
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
Published: 2024-03-27 (Crawled : 13:30) - globenewswire.com
AVTE M | $25.3 0.24% 0.43% 110K
|
Professional, Scientific, and T...
|
| O: 6.78%
H: 7.19%
C: 4.05%
conference international trial therapeutics
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
Published: 2024-03-25 (Crawled : 20:00) - globenewswire.com
AVTE M | $25.3 0.24% 0.43% 110K
|
Professional, Scientific, and T...
|
| O: -1.48%
H: 2.91%
C: -3.39%
business therapeutics results
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
Published: 2024-03-06 (Crawled : 13:00) - globenewswire.com
PEPG | $12.2 -6.15% -6.56% 44K
|
|
| O: -2.65%
H: 4.17%
C: -4.82%
AVTE M | $25.3 0.24% 0.43% 110K
|
Professional, Scientific, and T...
|
| O: -2.08%
H: 7.76%
C: 6.73%
BPMC | $85.18 -2.37% -2.42% 510K
|
Health Technology
|
| O: -0.75%
H: 3.12%
C: 1.55%
therapeutics
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
Published: 2023-11-20 (Crawled : 22:00) - globenewswire.com
AVTE M | $25.3 0.24% 0.43% 110K
|
Professional, Scientific, and T...
|
| O: -1.79%
H: 3.93%
C: 1.75%
av-101 treatment hypertension trial therapeutics
Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
Published: 2023-11-13 (Crawled : 15:30) - biospace.com/
AVTE M | $25.3 0.24% 0.43% 110K
|
Professional, Scientific, and T...
|
| O: -0.79%
H: 12.06%
C: 9.32%
business therapeutics financial results
Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights
Published: 2023-08-14 (Crawled : 12:00) - globenewswire.com
AVTE M | $25.3 0.24% 0.43% 110K
|
Professional, Scientific, and T...
|
| O: -2.16%
H: 4.91%
C: -0.2%
business therapeutics results
Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors
Published: 2023-07-11 (Crawled : 21:00) - globenewswire.com
PEPG | $12.2 -6.15% -6.56% 44K
|
|
| O: 1.88%
H: 3.23%
C: -1.96%
AVTE M | $25.3 0.24% 0.43% 110K
|
Professional, Scientific, and T...
|
| O: 1.67%
H: 2.3%
C: 0.77%
BPMC | $85.18 -2.37% -2.42% 510K
|
Health Technology
|
| O: 1.32%
H: 1.0%
C: 0.95%
therapeutics
Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference
Published: 2023-06-01 (Crawled : 12:00) - globenewswire.com
AVTE M | $25.3 0.24% 0.43% 110K
|
Professional, Scientific, and T...
|
| O: 0.06%
H: 6.52%
C: 3.26%
conference global therapeutics
Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference
Published: 2023-05-22 (Crawled : 17:00) - globenewswire.com
AVTE M | $25.3 0.24% 0.43% 110K
|
Professional, Scientific, and T...
|
| O: 0.38%
H: 1.26%
C: -3.28%
av-101 conference international therapeutics
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
Published: 2023-05-15 (Crawled : 20:00) - globenewswire.com
AVTE M | $25.3 0.24% 0.43% 110K
|
Professional, Scientific, and T...
|
| O: -3.94%
H: 1.93%
C: -3.65%
business therapeutics results
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 47% | 53% |
Top 10 Gainers
KAVL | $6.3 135.96% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.3704 -5.27% 43.09% 1.6M
|
Health Technology
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
HUBC | $1.95 50.0% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.35 33.65% 24.62% 53M
|
Health Technology
OMQS | $0.7038 35.35% 24.3% 3.5M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
EEIQ | $1.16 27.46% 20.86% 6.9K
|
Educational Services
Last 48 Hours Insiders Buying
RMCF | $3.56 -7.2% 7.1K
|
Consumer Non-Durables
|
20:10